Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis

Hyundai Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis

Treatments: Drug: Levotuss

Study type: Interventional

Funder types: Industry

Identifiers

NCT03489837

HOB-048

Details and patient eligibility

About

A randomized, double-blind, multicenter, active-controlled phase III study to evaluate the efficacy and safety of Levotuss CR tab. in comparison with Levotuss syrup in patients with cough due to acute or chronic bronchitis

Enrollment: 272 patients

Sex: All

Ages: 19 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• moderate, severe, very severe non-productive cough patients

Exclusion criteria

• Patients receiving a concomitant therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

272 participants in 2 patient groups

Levotuss CR tab

Experimental group

Description:

oral taken

Treatment:

Drug: Levotuss

Levotuss syrup

Active Comparator group

Description:

oral taken

Treatment:

Drug: Levotuss